David Erritzoe is the clinical director of the Centre for Psychedelic Research at Imperial College London. His work focuses on brain imaging (PET/(f)MRI).
From his profile at Imperial College London:
“Currently, he runs lab-based multi-modal brain imaging studies [often using pharmacological challenges] focusing on serotonin/dopamine/opiate neurotransmission as well as larger-scale prospective, naturalistic studies with online assessments and/or field-based data collection. Specifically, in the Centre for Psychedelic Research [where David is Clinical Director], studies are undertaken together with Prof Nutt and Dr Carhart-Harris, investigating brain mechanisms and therapeutic potential of MDMA and classic psychedelics.”
He is also an academic clinical lecturer.
He sits on the scientific advisory board of Mydecine.
Notable Research Papers
- Effects of psilocybin therapy on personality structure (Erritzoe et al., 2018)
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (Carhart-Harris et al., 2016)
- The dopamine theory of addiction: 40 years of highs and lows (Nutt et al., 2015)
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (Carhart-Harris et al., 2012)